Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

被引：0

作者：

Leleu, Xavier ^{[1
,2
]}

Beksac, Meral ^{[3
]}

Chou, Takaaki ^{[4
]}

Dimopoulos, Meletios ^{[5
]}

Yoon, Sung-Soo ^{[6
]}

Prince, Henry Miles ^{[7
]}

Pour, Ludek ^{[8
]}

Shelekhova, Tatiana ^{[9
]}

Chari, Ajai ^{[10
]}

Khurana, Monica ^{[11
]}

Obreja, Mihaela ^{[11
]}

Qi, Ming ^{[12
]}

Oriol, Albert ^{[13
]}

Siegel, David ^{[14
]}

机构：

[1] Chu, Poitiers, France

[2] Inserm 1402CIC, Poitiers, France

[3] Ankara Univ, Ankara, Turkey

[4] Niigata Canc Ctr Hpt, Niigata, Japan

[5] Natl & Kapodistrian Univ Athens, Sch Med, Hematol & Med Oncol, Dept Clin Therapeut,Sch Med, Athens, Greece

[6] Seoul Natl Univ, Seoul, South Korea

[7] Peter MacCallum Canc Inst, East Melbourne, Australia

[8] Univ Hosp Brno, Brno, Czech Republic

[9] Clin Profess Pathol, Saratov, Russia

[10] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[11] Amgen Inc, Thousand Oaks, CA USA

[12] Janssen Res & Dev LLC, Spring House, PA USA

[13] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain

[14] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

MM; multiple myeloma; carfilzomib; cross-study comparison; weekly dosing; KdD;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-040

引用

页码：S288 / S288

页数：1

共 12 条

[1] Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies
Leleu, Xavier
Beksac, Meral
Chou, Takaaki
Dimopoulos, Meletios
Yoon, Sung-Soo
Prince, H. Miles
Pour, Ludek
Shelekhova, Tatiana
Chari, Ajai
Khurana, Monica
Zhang, Jianqi
Obreja, Mihaela
Qi, Ming
Oriol, Albert
Siegel, David
LEUKEMIA & LYMPHOMA, 2021, 62 (02) : 358 - 367
[2] Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, ARROW, and CHAMPION-1 trials
Moreau, Philippe
Stewart, Keith A.
Dimopoulos, Meletios
Siegel, David
Facon, Thierry
Berenson, James
Raje, Noopur
Berdeja, Jesus G.
Orlowski, Robert Z.
Yang, Hui
Ma, Haijun
Klippel, Zandra
Zahlten-Kumeli, Anita
Mezzi, Khalid
Iskander, Karim
Mateos, Maria-Victoria
CANCER MEDICINE, 2020, 9 (09): : 2989 - 2996
[3] Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison
Weisel, Katja
Nooka, Ajay K.
Terpos, Evangelos
Spencer, Andrew
Goldschmidt, Hartmut
Dirnberger, Franziska
DeCosta, Lucy
Yusuf, Akeem
Kumar, Shaji
LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1887 - 1896
[4] Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States
Kumar, Shaji K.
Majer, Istvan
Panjabi, Sumeet
Medhekar, Rohan
Campioni, Marco
Dimopoulos, Meletios A.
EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (06) : 687 - 696
[5] A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly
Leleu, Xavier
Chari, Ajai
Richard, Shambavi
Khurana, Monica
Yusuf, Akeem
Usmani, Saad Z.
EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (12) : 1049 - 1058
[6] Weekly 20/56mg/m2 Carfilzomib, Lenalidomide and Dexamethasone until progression in Early Relapsed Refractory Multiple Myeloma
Gruchet, Cecile
Richez, Valentine
Guidez, Stephanie
Sabirou, Florence
Moya, Niels
Levy, Anthony
Bobin, Arthur
Gardeney, Helene
Nsiala, Laly
Machet, Antoine
Fouquet, Guillemette
Azais, Isabelle
Durand, Geraldine
Avet-Loiseau, Herve
Leleu, Xavier
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E258 - E258
[7] Trial in Progress: Once-Weekly vs Twice-Weekly Carfilzomib (K) Dosing in Combination with Lenalidomide (R) and Dexamethasone (d) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Leleu, Xavier
Beksac, Meral
Mateos, Maria-Victoria
Pour, Ludek
Weisel, Katja
Coriu, Daniel
Obreja, Michaela
Goldrick, Amanda
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S332 - S333
[8] Patient-Reported Outcomes (PROs) From the Phase 3 ARROW Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)
Moreau, Philippe
Kumar, Shaji
Boccia, Ralph
Iida, Shinsuke
Goldschmidt, Hartmut
Cocks, Kim
Zahlten-Kumeli, Anita
Yucel, Emre
Panjabi, Sumeet
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S240 - S240
[9] Carfilzomib 20/45 or 20/56 mg/m2 infused over 30 min in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma
Badros, Ashraf
Papadopoulos, Kyriakos P.
Zojwalla, Naseem
Ruey, Ju
Lee, Jiuan
Siegel, David S.
LEUKEMIA & LYMPHOMA, 2013, 54 : 17 - 18
[10] Once-Weekly 1.6 mg/m2 Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy
Yong Tang
Ye-hua Yu
Yi-yun Yao
Li-fang Zou
Hong-ju Dou
Lei Wang
Qi Zhu
Indian Journal of Hematology and Blood Transfusion, 2017, 33 : 22 - 30

← 1 2 →